Bristol-Myers Squibb Co
BMY46.350USD
+0.150+0.32%
Đóng cửa 09/15, 16:00（ET）Báo giá bị trễ 15 phút
94.32BVốn hóa
18.68P/E TTM
Thêm thông tin về Bristol-Myers Squibb Co Công ty
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Thông tin công ty
Mã chứng khoánBMY
Tên công tyBristol-Myers Squibb Co
Ngày IPOMar 17, 1980
Giám đốc điều hànhDr. Christopher S. (Chris) Boerner, Ph.D.
Số lượng nhân viên34100
Loại chứng khoánOrdinary Share
Kết thúc năm tài chínhMar 17
Địa chỉRoute 206 And Province Line Road
Thành phốPRINCETON
Sàn giao dịch chứng khoánNYSE Consolidated
Quốc giaUnited States of America
Mã bưu điện08543
Điện thoại16092524621
Trang webhttps://www.bms.com
Mã chứng khoánBMY
Ngày IPOMar 17, 1980
Giám đốc điều hànhDr. Christopher S. (Chris) Boerner, Ph.D.
Lãnh đạo công ty
Tên
Tên/Chức vụ
Chức vụ
Tỷ lệ sở hữu cổ phần
Thay đổi
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.84K
+6.22%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
--
--
Xem thêm
Tên
Tên/Chức vụ
Chức vụ
Tỷ lệ sở hữu cổ phần
Thay đổi
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.84K
+6.22%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Phân tích doanh thu
Tiền tệ: USDThời gian cập nhật: CN, 6 Th07
Tiền tệ: USDThời gian cập nhật: CN, 6 Th07
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Theo Doanh nghiệpUSD
Tên
Doanh thu
Tỷ trọng
Eliquis
3.56B
31.83%
Opdivo
2.27B
20.30%
Revlimid
936.00M
8.36%
Orencia
770.00M
6.87%
Pomalyst/Imnovid
659.00M
5.88%
Khác
3.00B
26.76%
Theo Khu vựcUSD
Tên
Doanh thu
Tỷ trọng
United States
7.87B
70.29%
International
3.11B
27.77%
other
218.00M
1.95%
Theo Doanh nghiệp
Theo Khu vực
Theo Doanh nghiệpUSD
Tên
Doanh thu
Tỷ trọng
Eliquis
3.56B
31.83%
Opdivo
2.27B
20.30%
Revlimid
936.00M
8.36%
Orencia
770.00M
6.87%
Pomalyst/Imnovid
659.00M
5.88%
Khác
3.00B
26.76%
Thống kê Cổ phần
Thời gian cập nhật: T6, 15 Th08
Thời gian cập nhật: T6, 15 Th08
Cổ đông
Loại Cổ đông
Cổ đông
Cổ đông
Tỷ trọng
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
4.88%
State Street Global Advisors (US)
4.65%
Charles Schwab Investment Management, Inc.
3.48%
JP Morgan Asset Management
3.31%
Khác
74.14%
Cổ đông
Cổ đông
Tỷ trọng
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
4.88%
State Street Global Advisors (US)
4.65%
Charles Schwab Investment Management, Inc.
3.48%
JP Morgan Asset Management
3.31%
Khác
74.14%
Loại Cổ đông
Cổ đông
Tỷ trọng
Investment Advisor
46.68%
Investment Advisor/Hedge Fund
25.41%
Research Firm
2.90%
Pension Fund
2.54%
Bank and Trust
2.27%
Sovereign Wealth Fund
1.75%
Hedge Fund
1.14%
Insurance Company
0.16%
Family Office
0.06%
Khác
17.09%
Cổ phần của tổ chức
Thời gian cập nhật: T3, 1 Th07
Thời gian cập nhật: T3, 1 Th07
Chu kỳ Báo cáo
Số lượng tổ chức
Cổ phiếu nắm giữ
Tỷ trọng
Thay đổi
2025Q2
4180
1.70B
83.46%
+31.40M
2025Q1
4287
1.68B
82.63%
+10.66M
2024Q4
4261
1.65B
81.14%
+17.04M
2024Q3
4116
1.60B
78.69%
-22.73M
2024Q2
4105
1.59B
78.35%
-83.12M
2024Q1
4118
1.64B
80.97%
+13.32M
2023Q4
4115
1.60B
78.83%
-46.39M
2023Q3
4042
1.63B
77.83%
-55.50M
2023Q2
4082
1.66B
78.77%
-34.93M
2023Q1
4110
1.66B
78.74%
-34.09M
Xem thêm
Hoạt động của Cổ đông
Tên
Cổ phiếu nắm giữ
Tỷ trọng
Thay đổi
Thay đổi %
Ngày
The Vanguard Group, Inc.
190.47M
9.36%
+1.45M
+0.77%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
97.77M
4.8%
+752.85K
+0.78%
Mar 31, 2025
State Street Global Advisors (US)
94.83M
4.66%
-310.27K
-0.33%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
60.61M
2.98%
+306.43K
+0.51%
Mar 31, 2025
JP Morgan Asset Management
69.89M
3.43%
+6.79M
+10.76%
Mar 31, 2025
Capital International Investors
66.47M
3.27%
+20.60M
+44.91%
Mar 31, 2025
Geode Capital Management, L.L.C.
45.45M
2.23%
+1.06M
+2.39%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
35.18M
1.73%
+2.58M
+7.92%
Dec 31, 2024
Columbia Threadneedle Investments (US)
29.03M
1.43%
+534.70K
+1.88%
Mar 31, 2025
Wellington Management Company, LLP
23.73M
1.17%
+17.75M
+296.96%
Mar 31, 2025
Xem thêm
ETF liên quan
Thời gian cập nhật: T4, 6 Th08
Thời gian cập nhật: T4, 6 Th08
Tên
Tỷ trọng
First Trust NASDAQ Pharmaceuticals ETF
5.91%
LSV Disciplined Value ETF
4.06%
iShares U.S. Pharmaceuticals ETF
3.88%
Coastal Compass 100 ETF
3.81%
Schwab U.S. Dividend Equity ETF
3.57%
Cullen Enhanced Equity Income ETF
3.33%
SPDR S&P Pharmaceuticals ETF
3.26%
Tema Oncology ETF
3.16%
VanEck Pharmaceutical ETF
3.1%
Brookstone Value Stock ETF
3%
Xem thêm
First Trust NASDAQ Pharmaceuticals ETF
Tỷ trọng5.91%
LSV Disciplined Value ETF
Tỷ trọng4.06%
iShares U.S. Pharmaceuticals ETF
Tỷ trọng3.88%
Coastal Compass 100 ETF
Tỷ trọng3.81%
Schwab U.S. Dividend Equity ETF
Tỷ trọng3.57%
Cullen Enhanced Equity Income ETF
Tỷ trọng3.33%
SPDR S&P Pharmaceuticals ETF
Tỷ trọng3.26%
Tema Oncology ETF
Tỷ trọng3.16%
VanEck Pharmaceutical ETF
Tỷ trọng3.1%
Brookstone Value Stock ETF
Tỷ trọng3%
Cổ tức
Tổng cộng
22.71B
USD đã được phân phối dưới dạng cổ tức trong 5 năm qua.
Ngày
Cổ tức
Ngày ghi sổ
Ngày thanh toán
Ngày không hưởng cổ tức
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Jun 14, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option
Jul 07, 2023
Aug 01, 2023
Jul 06, 2023
Mar 03, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023
Apr 10, 2023
May 01, 2023
Apr 06, 2023
Dec 08, 2022
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023
Jan 06, 2023
Feb 01, 2023
Jan 05, 2023
Sep 14, 2022
BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022
Oct 07, 2022
Nov 01, 2022
Oct 06, 2022
Xem thêm
Chia tách cổ phiếu
Ngày
Loại
Tỷ lệ
Không có dữ liệu
Ngày
Loại
Tỷ lệ
Không có dữ liệu
